Jared Weiss

6.8k total citations · 4 hit papers
53 papers, 3.7k citations indexed

About

Jared Weiss is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Jared Weiss has authored 53 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 15 papers in Otorhinolaryngology. Recurrent topics in Jared Weiss's work include Cancer Immunotherapy and Biomarkers (26 papers), Head and Neck Cancer Studies (15 papers) and Lung Cancer Research Studies (14 papers). Jared Weiss is often cited by papers focused on Cancer Immunotherapy and Biomarkers (26 papers), Head and Neck Cancer Studies (15 papers) and Lung Cancer Research Studies (14 papers). Jared Weiss collaborates with scholars based in United States, Japan and South Korea. Jared Weiss's co-authors include Tanguy Y. Seiwert, Jonathan D. Cheng, Joseph P. Eder, Laura Q.M. Chow, Barbara Burtness, Ranee Mehra, Christine K. Gause, Jared Lunceford, Karl Heath and Raanan Berger and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jared Weiss

50 papers receiving 3.7k citations

Hit Papers

Safety and clinical activity of pembrolizumab for treatme... 2016 2026 2019 2022 2016 2017 2018 2022 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
    2016 1.3k citations Tanguy Y. Seiwert, Barbara Burtness et al. The Lancet Oncology profile →
  2. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
    2017 497 citations Joshua Bauml, Tanguy Y. Seiwert et al. Journal of Clinical Oncology profile →
  3. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
    2018 329 citations Ranee Mehra, Tanguy Y. Seiwert et al. British Journal of Cancer profile →
  4. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
    2022 269 citations Jared Weiss, Sai‐Hong Ignatius Ou et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jared Weiss United States 27 3.0k 1.2k 921 808 702 53 3.7k
Seungwon Kim United States 36 1.8k 0.6× 831 0.7× 562 0.6× 1.6k 2.0× 846 1.2× 119 4.0k
Ani Sarkis Balmanoukian United States 31 2.9k 1.0× 1.1k 0.9× 1.1k 1.2× 164 0.2× 399 0.6× 74 3.5k
Armin Schueler Germany 11 2.2k 0.7× 1.6k 1.4× 258 0.3× 1.8k 2.2× 962 1.4× 18 3.8k
Panagiota Economopoulou Greece 26 1.4k 0.5× 597 0.5× 392 0.4× 297 0.4× 891 1.3× 105 2.7k
Paul M. Clément Belgium 33 1.5k 0.5× 1.3k 1.1× 294 0.3× 584 0.7× 1.4k 1.9× 136 4.1k
Jean‐Pascal Machiels Belgium 29 1.6k 0.5× 1.1k 1.0× 338 0.4× 255 0.3× 806 1.1× 137 3.1k
Johnny Kao United States 31 1.0k 0.3× 1.2k 1.0× 580 0.6× 792 1.0× 435 0.6× 76 2.9k
Matthew G. Fury United States 38 2.1k 0.7× 1.3k 1.1× 338 0.4× 1.2k 1.5× 881 1.3× 165 4.4k
Paul B. Romesser United States 25 958 0.3× 865 0.7× 342 0.4× 420 0.5× 654 0.9× 112 2.7k
Pol Specenier Belgium 21 1.1k 0.4× 542 0.5× 206 0.2× 450 0.6× 624 0.9× 84 1.9k

Countries citing papers authored by Jared Weiss

Since Specialization
Citations

This map shows the geographic impact of Jared Weiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jared Weiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jared Weiss more than expected).

Fields of papers citing papers by Jared Weiss

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jared Weiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jared Weiss. The network helps show where Jared Weiss may publish in the future.

Co-authorship network of co-authors of Jared Weiss

This figure shows the co-authorship network connecting the top 25 collaborators of Jared Weiss. A scholar is included among the top collaborators of Jared Weiss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jared Weiss. Jared Weiss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Seiwert, Tanguy Y., Sophie Wildsmith, Jérôme Fayette, et al.. (2024). Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma. Cancer Immunology Immunotherapy. 73(4). 70–70. 6 indexed citations
2.
Shen, Colette J., Jessica M. Frakes, Trevor Hackman, et al.. (2024). Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.. Journal of Clinical Oncology. 42(16_suppl). 6035–6035. 3 indexed citations
3.
Thomas, Sajeve, Brian S. Henick, Rom S. Leidner, et al.. (2024). Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2542–2542.
4.
Haddad, Robert I., Tanguy Y. Seiwert, Laura Q.M. Chow, et al.. (2022). Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 10(2). e003026–e003026. 54 indexed citations
5.
Li, Hongxia, Emily B. Harrison, Huizhong Li, et al.. (2022). Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration. Nature Communications. 13(1). 2154–2154. 75 indexed citations
6.
Weiss, Jared, Ashish V. Chintakuntlawar, Katharine A. Price, et al.. (2022). PDS0101, a novel type I interferon and CD8 T-cell activating immunotherapy, in combination with pembrolizumab in subjects with recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. 40(16_suppl). 6041–6041. 3 indexed citations
7.
8.
Das, Millie, Sukhmani K. Padda, Jared Weiss, & Taofeek K. Owonikoko. (2021). Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion. Advances in Therapy. 38(11). 5431–5451. 24 indexed citations
9.
Cohen, Ezra E.W., Michael J. Pishvaian, Dale R. Shepard, et al.. (2019). A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 7(1). 342–342. 45 indexed citations
10.
Segal, Neil H., Sai‐Hong Ignatius Ou, Ani Sarkis Balmanoukian, et al.. (2019). Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. European Journal of Cancer. 109. 154–161. 68 indexed citations
11.
Seiwert, Tanguy Y., Robert I. Haddad, Joshua Bauml, et al.. (2018). Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC). Cancer Research. 78(13_Supplement). LB–339. 34 indexed citations
12.
Mehra, Ranee, Tanguy Y. Seiwert, Shilpa Gupta, et al.. (2018). Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. British Journal of Cancer. 119(2). 153–159. 329 indexed citations breakdown →
13.
Bauml, Joshua, Tanguy Y. Seiwert, David G. Pfister, et al.. (2017). Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. Journal of Clinical Oncology. 35(14). 1542–1549. 497 indexed citations breakdown →
14.
Seiwert, Tanguy Y., Barbara Burtness, Ranee Mehra, et al.. (2016). Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. The Lancet Oncology. 17(7). 956–965. 1275 indexed citations breakdown →
15.
Seiwert, Tanguy Y., Jared Weiss, Shrujal S. Baxi, et al.. (2016). A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.. Journal of Clinical Oncology. 34(15_suppl). TPS6101–TPS6101. 28 indexed citations
16.
Weiss, Jared, et al.. (2016). Stigma, self-blame, and satisfaction with care among patients with lung cancer. Journal of Psychosocial Oncology. 35(2). 166–179. 37 indexed citations
17.
Weiss, Jared, et al.. (2014). Public attitudes about lung cancer: stigma, support, and predictors of support. Journal of Multidisciplinary Healthcare. 7. 293–293. 17 indexed citations
18.
Keating, Karen, et al.. (2013). Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital. Journal of Oncology Pharmacy Practice. 20(6). 409–416. 26 indexed citations
19.
Weiss, Jared, Drew Moghanaki, John P. Plastaras, & Daniel G. Haller. (2009). Improved Patient and Regimen Selection in Locally Advanced Rectal Cancer: Who, How, and What Next?. Clinical Colorectal Cancer. 8(4). 194–199. 6 indexed citations
20.
Weiss, Jared, Aaron W. McGee, William Stewart, et al.. (2004). Neonatal hypoxia suppresses oligodendrocyte Nogo-A and increases axonal sprouting in a rodent model for human prematurity. Experimental Neurology. 189(1). 141–149. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seungwon Kim Breakdown of academic impact, for papers by Ani Sarkis Balmanoukian Breakdown of academic impact, for papers by Armin Schueler Breakdown of academic impact, for papers by Panagiota Economopoulou Breakdown of academic impact, for papers by Paul M. Clément Breakdown of academic impact, for papers by Jean‐Pascal Machiels Breakdown of academic impact, for papers by Johnny Kao Breakdown of academic impact, for papers by Matthew G. Fury Breakdown of academic impact, for papers by Paul B. Romesser Breakdown of academic impact, for papers by Pol Specenier
Rankless by CCL
2026